Concepedia

David Tamang

DT

Statistics

Publications

19

Citations

2.1K

H-Index

16

Active since

2004

Affiliations

Acetylon Pharmaceuticals (United States)(Current)

Dana-Farber Cancer Institute

Massachusetts General Hospital

Harvard University

Medical College of Wisconsin

David Tamang is an author at Acetylon Pharmaceuticals (United States) specializing in medicine, immunology, and immunotherapy.

Top concepts

Publications per year

2004–2020

19

Publications

19

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood · 2012 · 594 citations · Full text

Immune epitope database analysis resource

Young‐Hee Kim, Julia Ponomarenko, Zhenggang Zhu et al. · Nucleic Acids Research · 2012 · 506 citations · Full text

, , +17

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, Noopur Raje, Sundar Jagannath et al. · Clinical Cancer Research · 2017 · 246 citations · Full text

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

Andrew J. Yee, William Bensinger, Jeffrey G. Supko et al. · The Lancet Oncology · 2016 · 193 citations

, , +8

Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition

William Hallett, Erik Ames, Milad Motarjemi et al. · The Journal of Immunology · 2008 · 137 citations · Full text

1–5 of 19